116 related articles for article (PubMed ID: 28765159)
21. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis.
Liu Z; Han L; Dong Y; Tan Y; Li Y; Zhao M; Xie H; Ju H; Wang H; Zhao Y; Zheng Q; Wang Q; Su J; Fang C; Fu S; Jiang T; Liu J; Li X; Kang C; Ren H
Oncotarget; 2016 Jan; 7(4):4680-94. PubMed ID: 26717039
[TBL] [Abstract][Full Text] [Related]
22. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
Ruano Y; Ribalta T; de Lope AR; Campos-Martín Y; Fiaño C; Pérez-Magán E; Hernández-Moneo JL; Mollejo M; Meléndez B
Am J Clin Pathol; 2009 Feb; 131(2):257-63. PubMed ID: 19141386
[TBL] [Abstract][Full Text] [Related]
23. Novel mechanisms and approaches in immunotherapy for brain tumors.
Finocchiaro G; Pellegatta S
Discov Med; 2015; 20(108):7-15. PubMed ID: 26321082
[TBL] [Abstract][Full Text] [Related]
24. Epidermal Growth Factor Receptor Expression Predicts Time and Patterns of Recurrence in Patients with Glioblastoma After Radiotherapy and Temozolomide.
Tini P; Nardone V; Pastina P; Battaglia G; Miracco C; Carbone SF; Sebaste L; Rubino G; Cerase A; Pirtoli L
World Neurosurg; 2018 Jan; 109():e662-e668. PubMed ID: 29061455
[TBL] [Abstract][Full Text] [Related]
25. EGFR targeted inhibition resistance: compensatory activation of ERBB family members in glioblastoma cancer stem-like cells promotes proliferation.
Gursel DB; Schlaff CD; Boockvar JA
Neurosurgery; 2012 Oct; 71(4):N17-8. PubMed ID: 22989968
[No Abstract] [Full Text] [Related]
26. EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling.
Liu F; Hon GC; Villa GR; Turner KM; Ikegami S; Yang H; Ye Z; Li B; Kuan S; Lee AY; Zanca C; Wei B; Lucey G; Jenkins D; Zhang W; Barr CL; Furnari FB; Cloughesy TF; Yong WH; Gahman TC; Shiau AK; Cavenee WK; Ren B; Mischel PS
Mol Cell; 2015 Oct; 60(2):307-18. PubMed ID: 26455392
[TBL] [Abstract][Full Text] [Related]
27. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
Lv S; Teugels E; Sadones J; De Brakeleer S; Duerinck J; Du Four S; Michotte A; De Grève J; Neyns B
Int J Oncol; 2012 Sep; 41(3):1029-35. PubMed ID: 22752145
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas.
Nicholas MK; Lukas RV; Jafri NF; Faoro L; Salgia R
Clin Cancer Res; 2006 Dec; 12(24):7261-70. PubMed ID: 17189397
[TBL] [Abstract][Full Text] [Related]
29. Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.
Shen Y; Li J; Nitta M; Futalan D; Steed T; Treiber JM; Taich Z; Stevens D; Wykosky J; Chen HZ; Carter BS; Becher OJ; Kennedy R; Esashi F; Sarkaria JN; Furnari FB; Cavenee WK; Desai A; Chen CC
Oncotarget; 2015 May; 6(14):11751-67. PubMed ID: 26059434
[TBL] [Abstract][Full Text] [Related]
30. Microglia in Cancer: For Good or for Bad?
da Fonseca AC; Amaral R; Garcia C; Geraldo LH; Matias D; Lima FR
Adv Exp Med Biol; 2016; 949():245-261. PubMed ID: 27714693
[TBL] [Abstract][Full Text] [Related]
31. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
[TBL] [Abstract][Full Text] [Related]
32. Molecular advances of brain tumors in radiation oncology.
Noda SE; El-Jawahri A; Patel D; Lautenschlaeger T; Siedow M; Chakravarti A
Semin Radiat Oncol; 2009 Jul; 19(3):171-8. PubMed ID: 19464632
[TBL] [Abstract][Full Text] [Related]
33. Loss of collapsin response mediator Protein1, as detected by iTRAQ analysis, promotes invasion of human gliomas expressing mutant EGFRvIII.
Mukherjee J; DeSouza LV; Micallef J; Karim Z; Croul S; Siu KW; Guha A
Cancer Res; 2009 Nov; 69(22):8545-54. PubMed ID: 19903856
[TBL] [Abstract][Full Text] [Related]
34. The infrequent simultaneous genetic alterations in glioblastoma multiforme (LOH 10, 17, 19q, TP53 mutation and EGFR amplification) with short clinical course.
Jesionek-Kupnicka D; Kulczycka D; Rieske P; Szybka M; Jabłońska J; Potemski P; Kolasa P; Liberski PP; Kordek R
Pol J Pathol; 2007; 58(2):79-85. PubMed ID: 17715673
[TBL] [Abstract][Full Text] [Related]
35. Increased transforming growth factor-β2 in epidermal growth factor receptor variant III-positive glioblastoma.
Zhang X; Wu A; Fan Y; Wang Y
J Clin Neurosci; 2011 Jun; 18(6):821-6. PubMed ID: 21511480
[TBL] [Abstract][Full Text] [Related]
36. Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme.
Stockhausen MT; Broholm H; Villingshøj M; Kirchhoff M; Gerdes T; Kristoffersen K; Kosteljanetz M; Spang-Thomsen M; Poulsen HS
Exp Cell Res; 2011 Jul; 317(11):1513-26. PubMed ID: 21514294
[TBL] [Abstract][Full Text] [Related]
37. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy.
Saikali S; Avril T; Collet B; Hamlat A; Bansard JY; Drenou B; Guegan Y; Quillien V
J Neurooncol; 2007 Jan; 81(2):139-48. PubMed ID: 17004103
[TBL] [Abstract][Full Text] [Related]
38. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
Murat A; Migliavacca E; Gorlia T; Lambiv WL; Shay T; Hamou MF; de Tribolet N; Regli L; Wick W; Kouwenhoven MC; Hainfellner JA; Heppner FL; Dietrich PY; Zimmer Y; Cairncross JG; Janzer RC; Domany E; Delorenzi M; Stupp R; Hegi ME
J Clin Oncol; 2008 Jun; 26(18):3015-24. PubMed ID: 18565887
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.
Martens T; Laabs Y; Günther HS; Kemming D; Zhu Z; Witte L; Hagel C; Westphal M; Lamszus K
Clin Cancer Res; 2008 Sep; 14(17):5447-58. PubMed ID: 18765536
[TBL] [Abstract][Full Text] [Related]
40. Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges.
Nicholas MK; Lukas RV; Chmura S; Yamini B; Lesniak M; Pytel P
Semin Oncol; 2011 Apr; 38(2):243-53. PubMed ID: 21421114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
